We read with interest an article published in The Lancet Oncology by Paul Brown and colleagues.1 In this multicentre, randomised, controlled, phase 3 trial, Brown and colleagues aimed to establish the ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

This offers hope to some patients who face an average survival rate of just several months. Read more at straitstimes.com.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Kerry S. Courneya, Ph.D., from the University of Alberta in Edmonton, Canada, and colleagues conducted a phase 3 randomized trial at 55 centers involving patients with resected colon cancer who ...

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA） ...

对于癌前病变患者 (如结直肠腺瘤)，癌症疫苗可通过激活特异性免疫应答，在细胞恶变前筑起防御屏障，阻断病变向癌症进展。而在手术、放化疗等常规治疗后，疫苗更能发挥"清道夫"作用——精准识别并清除残留癌细胞，显著降低复发转移风险。

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma ...

As brain tumors grow, they must do one of two things: push against the brain or use finger-like extensions to invade and destroy surrounding ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

Find the latest Evaxion A/S (EVAX) stock quote, history, news and other vital information to help you with your stock trading and investing.

today announced positive 1-year event free survival (EFS), overall survival and safety clinical trial data updates from the 40 patient treatment arm of its Phase 2b clinical trial of immunotherapy ...